PBYI
What one share of Puma Biotechnology holds
Pharmaceutical Preparations
We are a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. We are currently commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers.
Puma Biotechnology’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $4.46 |
|---|---|
| Profit | $0.52 |
| Capex (buildings and equipment) | −$0.00 |
| Free cash flow | $0.79 |
| Cash and investments | $1.84 |
| Debt | $2.00 |
| Book value | $2.71 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$8.29 | $0.13 | −$4.38 | — | $5.70 |
| 2017 | $0.74 | −$7.85 | $0.01 | −$4.65 | — | $1.42 |
| 2018 | $6.62 | −$2.99 | $0.01 | −$0.65 | — | $0.90 |
| 2019 | $7.02 | −$1.95 | $0.01 | $0.57 | — | $0.45 |
| 2020 | $5.69 | −$1.52 | $0.00 | $0.02 | — | −$0.15 |
| 2021 | $6.23 | −$0.72 | $0.00 | $0.51 | — | −$0.06 |
| 2022 | $5.08 | $0.00 | $0.00 | −$0.35 | — | $0.47 |
| 2023 | $4.96 | $0.45 | $0.00 | $0.57 | — | $1.12 |
| 2024 | $4.69 | $0.62 | $0.00 | $0.79 | — | $1.88 |
| 2025 | $4.51 | $0.61 | $0.00 | $0.82 | — | $2.59 |